MDK-NCL and MDK–syndecan interactions between tumor cells, stromal cells, and immune cells were found to be increased in tumors with acquired resistance to CDK4/6 inhibitors, though it was not associated with intrinsic resistance and early progression [125]. The gene discussed is MDK; the disease is neoplasm.